Neurological Disease News and Research

RSS

Gaucher disease: FDA approves VPRIV

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.

26 Feb 2010

Emerging concepts from gene regulation studies in immune cells

The seventh meeting in the “Emergence and Convergence” series jointly organized by La Fondation IPSEN and Nature brings together today in San Antonio (Texas, USA) leading experts to discuss concepts emerging from gene regulation studies in immune cells that have led to insights into the initiation and maintenance of epigenetic chromatin marks necessary for proper differentiation and function of these cells in the immune system.

19 Feb 2010

GSK decides to remove potentially hazardous zinc from denture adhesive products

GlaxoSmithKline, the maker of popular denture adhesives Poligrip and Super Poligrip, announced today that it will remove zinc from all of its denture adhesive products. The pharmaceutical giant has added the potentially hazardous mineral to its adhesives for decades, despite overwhelming evidence that consuming large quantities of zinc over an extended period of time can cause serious neurological damage.

19 Feb 2010

Two UCSF scientists selected for Potamkin Prize for their achievements in research on dementias

Two UCSF scientists have been selected for the American Academy of Neurology's prestigious Potamkin Prize, for their "outstanding achievements" in research on dementias.

19 Feb 2010

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

Lennart Mucke, MD, Director of the Gladstone Institute of Neurological Disease (GIND), has been named a recipient of the American Academy of Neurology's prestigious Potamkin Prize.

19 Feb 2010

CoAxia completes enrollment in NeuroFlo Perfusion Augmentation Therapy trial for ischemic stroke

CoAxia™, Inc. of Maple Grove, MN, announced today the completion of enrollment in its SENTIS randomized, controlled, pivotal trial of NeuroFlo™ Perfusion Augmentation Therapy as an acute interventional treatment for ischemic stroke. The Company plans to complete data collection and analysis of results in Q3 of 2010 and, if warranted, submit a PMA to the US FDA.

15 Feb 2010

Researchers uncover new mechanism to protect individuals from serious complications of obesity

Although obesity is a risk factor for diabetes and coronary heart disease worldwide, only some obese individuals go on to develop these metabolic complications, while others are relatively protected. Defining these protective factors could help scientists prevent disease in the wider population.

4 Feb 2010

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.

28 Jan 2010

Researchers identify new drugs to protect brain cells from neurological disease

Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.

27 Jan 2010

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

EMD Serono announces results from CLARITY Phase III trial in MS patients

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).

21 Jan 2010

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

20 Jan 2010

New genetic risk factor for Parkinson's disease identified

An international team of doctors and human geneticists has identified a new genetic risk factor for Parkinson's disease. The institutions involved in the study were the Institute of Human Genetics of Helmholtz Zentrum München and Technische Universität München, the Neurological Clinic of Ludwig-Maximilians-Universität Munich (LMU) and the Mitochondrial Research Group of Newcastle University, Newcastle upon Tyne, UK.

18 Jan 2010

First Houston patient treated with FDA-approved liquid material for brain aneurysm

A 68-year-old woman became the first patient in Houston to have her brain aneurysm treated with a recently FDA-approved liquid material instead of traditional open skull surgery or platinum coils.

18 Jan 2010

Joubert Syndrome - an inherited neurological disease found among Ashkenazi Jews

Two scientists from Cold Spring Harbor Laboratory (CSHL) are part of an international team that has discovered a genetic mutation that causes Joubert Syndrome. JBTS, as it is commonly called, is a devastating inherited neurological disease that is very rare in the general population but found relatively more often among Ashkenazi Jews.

18 Jan 2010

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

"Our study reveals the interaction of genetic and environmental factors such as dietary habits in the pathogenesis of Parkinson's disease," explained Dr. Matthias Elstner of the Neurological Clinic of LMU and Helmholtz Zentrum M-nchen, lead author of the study.

18 Jan 2010

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.

13 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

Scientists at the Gladstone Institute of Virology and Immunology (GIVI) have discovered a new agent that might inhibit the infectivity of HIV. The agent, surfen, impairs the action of a factor in semen that greatly enhances the viral infection.

5 Jan 2010

SVA submits the first clinical trial application for HFMD vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China.

28 Dec 2009

Neurological Disease News and Research

Gaucher disease: FDA approves VPRIV

Emerging concepts from gene regulation studies in immune cells

GSK decides to remove potentially hazardous zinc from denture adhesive products

Two UCSF scientists selected for Potamkin Prize for their achievements in research on dementias

Gladstone MD receives Potamkin Prize for identifying new avenues in Alzheimer's research

CoAxia completes enrollment in NeuroFlo Perfusion Augmentation Therapy trial for ischemic stroke

Researchers uncover new mechanism to protect individuals from serious complications of obesity

IRSF announces first 2010 ANGEL Grant for testing potential Rett Syndrome therapies

Researchers identify new drugs to protect brain cells from neurological disease

Geron collaborates to explore hESC-based product for Alzheimer’s disease

EMD Serono announces results from CLARITY Phase III trial in MS patients

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

New genetic risk factor for Parkinson's disease identified

First Houston patient treated with FDA-approved liquid material for brain aneurysm

Joubert Syndrome - an inherited neurological disease found among Ashkenazi Jews

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

GIND scientists identify major role of TDP-43 in two neurodegenerative diseases

MedGenesis Therapeutix enters into license agreement with Amgen

GIVI scientists discover anti-HIV molecule that enhances infection, reduces transmission

SVA submits the first clinical trial application for HFMD vaccine in China

Neuroscience - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News